AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
RECENT ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
